Evidence map›Paper›PMID 21344263›Full record

ReviewVirchows Archiv : an international journal of pathology2011

The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers.

Marco Volante, Luisella Righi, Alfredo Berruti, Guido Rindi, Mauro Papotti

Abstract readReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Application of Metabolic Reprogramming to Cancer Imaging and Diagnosis.International journal of molecular sciences · 2022
    Review
  5. Review
  6. Article
  7. Article
  8. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marco VolanteDivisions of Pathology, University of Turin at San Luigi Hospital, Orbassano, Torino, Italy.
Luisella Righi
Alfredo Berruti
Guido Rindi
Mauro Papotti

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine neoplasms (NEN) develop in many organs, and although they share some pathological and clinical features, significant differences do exist among different tumor types and locations. The correct classification of NENs is based on the recently published WHO classification according to the various locations, and is relevant for the appropriate treatment in each group. The apparently easy diagnostic categorization in well-differentiated NENs, called neuroendocrine tumors, and poorly differentiated NENs, called neuroendocrine carcinomas, is complicated by the existence, among others, of different terminologies, morphological criteria of malignancy, combined exocrine-endocrine tumors, as well as of heterogeneous diagnostic, prognostic, and predictive markers. The present paper is an overview of the most frequently asked questions and an attempt to provide practical answers related to NEN diagnosis in the daily pathology work.

Indexed as

HumansNeuroendocrine TumorsWorld Health Organization

Identifiers

PMID21344263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.